Project 2: STAT3 as a trigger for T1D
项目 2:STAT3 作为 T1D 的触发因素
基本信息
- 批准号:10576386
- 负责人:
- 金额:$ 17.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-17 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdoptive TransferAllelesAnimal ModelAnimalsAntigensAutoantibodiesAutoimmuneAutoimmune DiabetesAutoimmunityB-LymphocytesCD8-Positive T-LymphocytesCell SurvivalCell surfaceCellsClinicalCollaborationsCritical PathwaysDefectDevelopmentDiabetes MellitusDiseaseEngineeringEpitheliumFOXP3 geneFamily memberGene ActivationGene ExpressionGenesGeneticGenetic TranscriptionHormonesHumanHuman GeneticsImmuneImmune ToleranceImmune systemInbred NOD MiceInfiltrationInsulinInsulin-Dependent Diabetes MellitusInterleukin-6Knock-in MouseKnowledgeLinkMHC Class II GenesMapsMediatingMendelian disorderMissense MutationModelingMusMutationNatural ImmunityOrganPathway interactionsPatientsPhenotypePhosphorylationPlayPopulationPredispositionProliferatingRegulatory T-LymphocyteReportingResearch PersonnelRoleSignal TransductionStat3 proteinStudy modelsSyndromeT-LymphocyteThymic epithelial cellThymus GlandTimeTissuesTranscription Factor 3ValidationVariantWorkadaptive immunitycentral tolerancecytokinecytopeniaexome sequencinggain of functiongain of function mutationimprovedinsightinsulin dependent diabetes mellitus onsetinsulitisisletlymphadenopathymouse modelnovelperipheral bloodperipheral tolerancesuccesssynergismtranscription factortransmission process
项目摘要
Project Summary/Abstract
Monogenic diseases that have a close association with the development of type 1 diabetes have been
informative for unraveling critical pathways that keep this disease in check. Examples of success using this
approach include the study of AIRE and FOXP3 which have been informative for identifying pathways in the
thymus and T regulatory cells that keep type 1 diabetes in check. Here, we will leverage the recent knowledge
that gain of function mutations (GOF) in STAT3 are tightly associated with the development of type 1 diabetes
by developing a robust animal model of the syndrome.
Our specific aims are:
Aim 1: Model the effects of STAT3 GOF in a novel mouse model of autoimmune diabetes
(NOD.STAT3K392R/+)
Aim 2: Identify and characterize key immune cell populations that are defective in the NOD.STAT3K392R/+
model and in patients with similar STAT3 GOF mutations
Aim 3: Identify how central tolerance is potentially altered in STAT3 GOF models
These studies will be performed in close collaboration with PPG projects 1 (Cooper) and 3 (Marson) and will
help improve our understanding of how the immune tolerance is controlled by STAT3 and how alterations in
this molecule can provoke type 1 daibetes.
项目总结/摘要
与1型糖尿病发展密切相关的单基因疾病已经被发现,
为解开控制这种疾病的关键途径提供了信息。成功使用此
方法包括AIRE和FOXP 3的研究,这些研究为确定
胸腺和T调节细胞,保持1型糖尿病的检查。在这里,我们将利用最近的知识,
STAT 3中的功能获得突变(GOF)与1型糖尿病的发生密切相关,
通过开发一个强大的综合症动物模型。
我们的具体目标是:
目的1:在新型自身免疫性糖尿病小鼠模型中模拟STAT 3 GOF的作用
(NOD.STAT3K392R/+)
目的2:鉴定和表征NOD.STAT3K392R/+缺陷的关键免疫细胞群体
模型和具有相似STAT 3 GOF突变的患者中
目的3:确定在STAT 3 GOF模型中中枢耐受性是如何潜在改变的
这些研究将与PPG项目1(库珀)和3(Marson)密切合作进行,并将
有助于我们更好地理解免疫耐受是如何由STAT 3控制的,以及STAT 3基因的改变是如何影响免疫耐受的。
这种分子可以刺激1型糖尿病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark S Anderson其他文献
The sickness unto Deaf
致聋之病
- DOI:
10.1038/ni0909-934 - 发表时间:
2009-09-01 - 期刊:
- 影响因子:27.600
- 作者:
James M Gardner;Mark S Anderson - 通讯作者:
Mark S Anderson
Mark S Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark S Anderson', 18)}}的其他基金
STAT3 variants as a rheostat of immune tolerance
STAT3 变体作为免疫耐受的变阻器
- 批准号:
10328097 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Tuning peptide specifities for T cell tolerance in Type 1 diabetes
调整 1 型糖尿病 T 细胞耐受性的肽特异性
- 批准号:
10630946 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Alterations of leukocyte integrin signaling leading to diabetes and autoimmunity
白细胞整合素信号的改变导致糖尿病和自身免疫
- 批准号:
10502136 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Project 2: STAT3 as a trigger for T1D
项目 2:STAT3 作为 T1D 的触发因素
- 批准号:
10328102 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Tuning peptide specifities for T cell tolerance in Type 1 diabetes
调整 1 型糖尿病 T 细胞耐受性的肽特异性
- 批准号:
10503923 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Alterations of leukocyte integrin signaling leading to diabetes and autoimmunity
白细胞整合素信号的改变导致糖尿病和自身免疫
- 批准号:
10683384 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
STAT3 variants as a rheostat of immune tolerance
STAT3 变体作为免疫耐受的变阻器
- 批准号:
10576375 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 17.54万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 17.54万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 17.54万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 17.54万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 17.54万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 17.54万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 17.54万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 17.54万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 17.54万 - 项目类别:














{{item.name}}会员




